26 September 2018
SpeeDx Begins Multisite U.S. Clinical Trials of ResistancePlus® MG
SpeeDx announced the start of patient testing in their multisite U.S.-based clinical trials for ResistancePlus® MG.
“This test is an exciting new development that will increase the precision of patient care for patients impacted by Mycoplasma genitalium – a common sexually transmitted infection with limited treatment options,” notes Dr Maria Trent, Professor of Pediatrics and Public Health at Johns Hopkins Medicine.
Read the full press release